Published 2022-09-09
Dio Mafazi Fabrianta Kurnia Penta Seputra Besut Daryanto


Objective: The purpose of this study was to determine the correlation of testicular tumor markers on the success of chemotherapy in my institution. Material & Methods: This research is a retrospective study single center using the medical record database at the span of the research period. The patient with testicular carcinoma who underwent complete chemotherapy between 2017 until 2022 was included. The data collected and analyzed by descriptive data and analytical correlation using SPSS Ver. 25. The comparation test using T-test and Anova. Results: A total of 31 testicular cancer patients were enrolled in the study. Fifteen patients were seminoma and 16 patients were non-seminoma. The mean age of patient at presentation of seminoma and non seminoma were 38.3 ± 17.03 and 30.74 ± 13.01. Most patients presented a karnofsky score about 79 ± 15. There was a negative correlation (r=-0.492) with a significant correlation between the types of testicular carcinoma cases and the response to chemotherapy (p=0.027).  There was a significant difference in cases of seminoma and non-seminoma to the success of the chemotherapy response (p=0.024). There was a positive correlation between serum β-HCG, AFP, LDH with serial chemotherapy result with a no significant correlation (p=0.879; p=0.242; and p=0.277). Conclusion: Most types of the testicular carcinoma responses to chemotherapy. Patients with seminoma pathology have better response to chemotherapy compared to non-seminoma.



chemoterapy, testicular cancer, tumor marker


Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of over-active bladder in the United States. World J Urol. 2003; 20: 327–336.

Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010; 29: 4–20.

Van Dijk MM, Wijkstra H, Debruyne FM, De La Rosette JJ, Michel MC. The role of nocturia in the quality of life of men with lower urinary tract symptoms. BJU Int. 2010; 105: 1141–1146.

Middelkoop HA, Smilde-van den Doel DA, Neven AK, Kamphuisen HA, Springer CP. Subjective sleep characteristics of 1,485 males and females aged 50–93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol A Biol Sci Med Sci. 1996; 51: M108–115.

Budaya TN, Daryanto B. Kemoterapi Kanker Urogenital. Universitas Brawijaya Press; 2020 Jul 31.

Hartmann, J. T., Bamberg, M. & Albers, P. Multidisciplinary treatment and prognosis of patients with central nervous metastases (CNs) from testicular germ cell tumour (GCT) origin [abstract 1607]. Proc. Am. Soc. Clin. Oncol. 2003; 22: 400.

Krege, s. et al. european consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the european Germ Cell Cancer Consensus Group (eGCCCG): part II. Eur. Urol. 2008; 53: 497–513.

Eble, J. N., sauter, G., epstein, J. I. & sesterhenn, I. A. (eds) WHO Classification of Tumours. Pathology and Genetics. Tumours of the Urinary System and Male Genital Organs Ch. 2004; 4: 250–262.

P D Simmonds 1, G M Mead, A H Lee, J M Theaker, K Dewbury, C J Smart. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? Cancer. 1995; 75: 1018–24.

Leibovitch 1, J S Little Jr, R S Foster, R G Rowland, R Bihrle, J P Donohue. (1996).Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol. 1995; 155: 952–4.

Copyright Information
Department of Urology, Faculty of Medicine/Airlangga University